ArticleSAGE open medicine2025
Doxorubicin, bleomycin, vinblastine, and dacarbazine for Hodgkin lymphoma: Real-world experience from a Los Angeles County hospital.
Article in SAGE open medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: While there are significant ongoing advancements in the management of Hodgkin lymphoma, doxorubicin + bleomycin + vinblastine + dacarbazine remains a preferred option for early stage Hodgkin lymphoma and is a frequently used first-line treatment globally. The aim of this retrospective study is to analyze real-world doxorubicin + bleomycin + vinblastine + dacarbazine outcomes from a safety net hospital setting. Methods: This retrospective cohort consisted of 69 adult patients with classical Hodgkin lymphoma who received first-line doxorubicin + bleomycin + vinblastine + dacarbazine at Harbor-UCLA Medical Center from 2009 to 2024. Early (I-II) and advanced (III-IV) stage patients were included. Results: The median patient age was 41 years old (range 18-71). There was balanced distribution of early stage (7.2% stage I, 40.6% stage II) and advanced stage (20.3% stage III, 31.9% stage IV) Hodgkin lymphoma. With a median of six cycles (range 2-7) of doxorubicin + bleomycin + vinblastine + dacarbazine, the complete response rate was 78.3% and overall response rate was 82.6%. Five-year progression-free survival was 70.7% (70.2% for stage I-II, 71.3% for stage III-IV). Overall survival at 5 years was 95.4% (100% for stages I-II, 91.5% for stages III-IV). Bleomycin-associated lung toxicity was observed in 10 (14.5%) patients, including one treatment-related death. Conclusions: Response rates and overall survival from this real-world cohort are comparable to previously published contemporary studies. The high complete response rate, 5-year progression-free survival, and 5-year overall survival in this study further support the robust curative potential of doxorubicin + bleomycin + vinblastine + dacarbazine and validate its continued use in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.